Summit Therapeutics (SMMT) Reports Q2 Loss of GBP0.02

Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.02).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Copart launches $10.50-per-share tender offer to acquire ACV
• Surgery Partners sells Idaho Falls facilities to Intermountain Health for $797M